
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 226 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
Export 122 results:
Author Title Type [ Year
Filters: Author is van Staa, T. P. [Clear All Filters]
“Postmarketing surveillance of the safety of cyclic etidronate”, Pharmacotherapy, vol. 18, pp. 1121-8, 1998.
, “Use of cyclical etidronate and prevention of non-vertebral fractures”, Br J Rheumatol, vol. 37, pp. 87-94, 1998.
, “Oral corticosteroids and fracture risk: relationship to daily and cumulative doses”, Rheumatology (Oxford), vol. 39, pp. 1383-9, 2000.
, “The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results”, Pharmacoepidemiol Drug Saf, vol. 9, pp. 359-66, 2000.
, “Use of nonsteroidal anti-inflammatory drugs and risk of fractures”, Bone, vol. 27, pp. 563-8, 2000.
, “Use of oral corticosteroids and risk of fractures”, J Bone Miner Res, vol. 15, pp. 993-1000, 2000.
, “Use of oral corticosteroids in the United Kingdom”, Qjm, vol. 93, pp. 105-11, 2000.
, “Epidemiology of fractures in England and Wales”, Bone, vol. 29, pp. 517-22, 2001.
, “Public health impact of adverse bone effects of oral corticosteroids”, Br J Clin Pharmacol, vol. 51, pp. 601-7, 2001.
, “Use of inhaled corticosteroids and risk of fractures”, J Bone Miner Res, vol. 16, pp. 581-8, 2001.
, “Use of statins and risk of fractures”, Jama, vol. 285, pp. 1850-5, 2001.
, “Does a fracture at one site predict later fractures at other sites? A British cohort study”, Osteoporos Int, vol. 13, pp. 624-9, 2002.
, “Incidence and natural history of Paget's disease of bone in England and Wales”, J Bone Miner Res, vol. 17, pp. 465-71, 2002.
, “Utility of medical and drug history in fracture risk prediction among men and women”, Bone, vol. 31, pp. 508-14, 2002.
, “Children and the risk of fractures caused by oral corticosteroids”, J Bone Miner Res, vol. 18, pp. 913-8, 2003.
, “Neutropenia and agranulocytosis in England and Wales: incidence and risk factors”, Am J Hematol, vol. 72, pp. 248-54, 2003.
, “Use of alpha-blockers and the risk of hip/femur fractures”, J Intern Med, vol. 254, pp. 548-54, 2003.
, “The use of inhaled corticosteroids in the United Kingdom and the Netherlands”, Respir Med, vol. 97, pp. 578-85, 2003.
, “5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study”, Gastroenterology, vol. 126, pp. 1733-9, 2004.
, “Are inhaled corticosteroids associated with an increased risk of fracture in children?”, Osteoporos Int, vol. 15, pp. 785-91, 2004.
, “Epidemiology of childhood fractures in Britain: a study using the general practice research database”, J Bone Miner Res, vol. 19, pp. 1976-81, 2004.
, “Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study”, Heart, vol. 90, pp. 859-65, 2004.
, “5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study”, Gut, vol. 54, pp. 1573-8, 2005.
, “The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database”, Rheumatology (Oxford), vol. 44, pp. 1394-8, 2005.
, “Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database”, Epilepsia, vol. 46, pp. 304-10, 2005.
, “Risk of hip/femur fractures in patients using antipsychotics”, Bone, vol. 37, pp. 864-70, 2005.
, “Severity of obstructive airway disease and risk of osteoporotic fracture”, Eur Respir J, vol. 25, pp. 879-84, 2005.
, “A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids”, Qjm, vol. 98, pp. 191-8, 2005.
, “Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis”, Arthritis Rheum, vol. 54, pp. 3104-12, 2006.
, “Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database”, Int J Epidemiol, vol. 35, pp. 1301-8, 2006.
, “Risk of aplastic anemia in patients using antiepileptic drugs”, Epilepsia, vol. 47, pp. 1232-6, 2006.
, “Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy”, Neurology, vol. 66, pp. 1318-24, 2006.
, “Fracture risk with intermittent high-dose oral glucocorticoid therapy”, Arthritis Rheum, vol. 56, pp. 208-14, 2007.
, “The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis”, Arthritis Rheum, vol. 57, pp. 1151-7, 2007.
, “Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids”, Rheumatology (Oxford), vol. 46, pp. 460-6, 2007.
, “Lithium use and the risk of fractures”, Bone, vol. 40, pp. 1252-8, 2007.
, “Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands”, Calcif Tissue Int, vol. 80, pp. 69-75, 2007.
, “Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib”, Arthritis Rheum, vol. 59, pp. 1105-11, 2008.
, “Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?”, J Intern Med, vol. 264, pp. 481-92, 2008.
, “Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?”, Pharmacoepidemiol Drug Saf, vol. 17, pp. 475-84, 2008.
, “Fracture outcomes related to persistence and compliance with oral bisphosphonates”, J Bone Miner Res, vol. 23, pp. 1569-75, 2008.
, “Individualizing the risks and benefits of postmenopausal hormone therapy”, Menopause, vol. 15, pp. 374-81, 2008.
, “Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?”, J Thromb Haemost, vol. 6, pp. 1500-6, 2008.
, “What is the harm-benefit ratio of Cox-2 inhibitors?”, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
, “A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example”, PLoS Med, vol. 6, p. e1000194, 2009.
, “Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates”, Osteoporos Int, vol. 20, pp. 1989-98, 2009.
, “How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database”, Thromb Haemost, vol. 101, pp. 527-34, 2009.
, “The pattern of risk of myocardial infarction in patients taking asthma medication: a study with the General Practice Research Database”, J Hypertens, vol. 27, pp. 1485-92, 2009.
, “The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates”, Qjm, vol. 102, pp. 35-42, 2009.
, “Study of adverse outcomes in women using testosterone therapy”, Maturitas, vol. 62, pp. 76-80, 2009.
,